Chitosan hydrogel for repairing nerve tissue

Patent metadata

Field	Value
Publication number	US-9623044-B2
Application number	US-201314414994-A
Country	US
Kind code	B2
Filing date	Jul 16, 2013
Priority date	Jul 19, 2012
Publication date	Apr 18, 2017
Grant date	Apr 18, 2017

Abstract

The present invention relates to chitosan hydrogel microparticles of a median size d50 comprised between 1 and 500 μm (obtained from a number distribution), the chitosan having a degree of acetylation of less than equal to 20% and its concentration in the hydrogel being comprised between 0.25 and 5% by weight based on a total weight of the hydrogel, for use in neuron regeneration and/or in the repair of the nervous system, advantageously of the central nervous system, and/or in the grafting of neurons and/or in the treatment of neurodegenerative diseases and/or in the treatment of paralyses.
It also relates to an implant comprising an aqueous suspension of microparticles mixed with Schwann cells and/or stem cells and/or trophic factors.

First claim

The invention claimed is:

1. A method of neuron regenerating and/or repairing of the nervous system, and/or grafting of neurons or precursors of neural cells, and/or treatment of neurodegenerative diseases, and/or treatment of ischemic wounds and/or treatment of paralyses, the method comprising:
administering, to a mammal in need thereof, an effective amount of chitosan hydrogel microparticles;
wherein said microparticles have a median size d50, obtained from a number distribution, of from 1 to 500 μm;
wherein said chitosan has a degree of acetylation of less than or equal to 20%;
wherein the concentration of chitosan in the hydrogel is from 0.25 to 5% by weight, based on the total weight of the hydrogel; and
wherein the microparticles are administered subsequent to a traumatic lesion of the nervous system of the mammal, which is a traumatic lesion of the spinal cord.

2. The method according to claim 1 , wherein the median size d50 of the microparticles is from 5 to 300 μm.

3. The method according to claim 1 wherein the degree of acetylation of the chitosan is less than 5%.

4. The method according to claim 1 , wherein the concentration of the chitosan in the hydrogel is less than 4% by weight, based on the total weight of the hydrogel.

5. The method according to claim 1 , wherein the hydrogel is a physical chitosan hydrogel, such that interactions responsible for the inter-chain cross-linking in the hydrogel are of a physical type.

6. The method according to claim 1 , comprising administering the microparticles in an aqueous suspension having a viscosity greater than 1000 Pa·s measured in a continuous mode at 22° C. for a shear rate of 0.001 s −1 .

7. The method according to claim 6 , wherein the aqueous suspension is in an injectable form or an implantable form.

8. The method according to claim 6 , comprising mixing the microparticles with a member selected from the group consisting of Schwann cells, stem cells, trophic factors, and a combination thereof.

9. The method according to claim 1 , wherein the mammal is a human being.

Assignees

• Univ Claude Bernard Lyon
• Inst Nat Sciences Appliquees Lyon
• Univ Jean Monnet Saint Etienne
• Centre Nat Rech Scient
• Inserm (Institut Nat De La Sante Et De La Rech Medicale)
• Univ Pierre Et Marie Curie Paris 6

Inventors

• Nothias Fatiha
• Soares Sylvia
• David Laurent
• Montembault Alexandra

Classifications

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P25/16

  Anti-Parkinson drugs · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61P25/02

  for peripheral neuropathies · CPC title